Drug intelligence / Profile preview

Metabose ER

Development stage: Unknown
Lead developer: El Dorado Bio Tech
Modality: Small Molecules
Administration: Oral

Overview

**Metabose ER** is an oral extended-release fixed-dose antidiabetic tablet marketed by El Dorado Bio Tech for **type 2 diabetes mellitus**. It combines **metformin hydrochloride 1000 mg** and **voglibose 0.3 mg**. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, while voglibose competitively inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate digestion and reducing postprandial glucose excursions. The product is used when diet, exercise, and single-agent therapy do not provide adequate glycemic control.

Brand names: Metabose ER

Targets

AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on Metabose ER.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabose ER.

Explore the full profile